Loading...

About Diag2Tec’s Team and Scientific Board

About Diag2Tec’s Team and Scientific Board 2016-10-24T15:19:27+00:00

Meet Our Executive Team

Pierre VIDAL
Pierre VIDALCEO and Co-Founder
Chief Executive Officer and Co-founder of Diag2Tec, Pierre has a PhD in Biology – Biochemistry and more than 20 years of experience in Medical Diagnosis and drug market, in Research Programs, Project Management, Business Strategy and strong Networking.
He has participated and created several companies with these past few years
Angélique BRUYER
Angélique BRUYERLaboratory Director and Co-Founder
Co-founder of Diag2Tec, Angélique has a Master in Molecular Biology. She has been Research Engineer into the group « Diagnosis and minimal residual disease of MM patients » CHU Montpellier, She has been in charge of in vitro culture of MM Cell lines and in charge of predictive signatures development.
Jérôme MOREAUX
Jérôme MOREAUXCSO and Co-Founder
Co-Founder of Diag2Tec, Jérôme is Associate Professor Hematology at Montpellier 1 University since 2014. He’s Group Leader of « Diagnosis and minimal residual disease of Mulitple Myeloma (MM) patients » into the laboratory « Monitoring Innovative Therapies » at the Montpellier University Hospital (CHU).
He has an worldwide recognition and strong expertise in MM pathologie

Diag2Tec Scientific Advisor Board

  • Jérôme Moreaux, PhD, Co-Founder, Associate Professor Hematology at Montpellier 1 University. Group Leader of « Diagnosis and minimal residual disease of Mulitple Myeloma (MM) patients » into the laboratory « Monitoring Innovative Therapies » at the Montpellier University Hospital (CHU).
  • Jean Luc Veyrune, PhD, Co-Founder, Engineer biologist within the unity of Cellular and Gene Therapy of Montpellier University Hospital and a member of INSERM-UM1 U1040 team. In charge for quality controls Therapy Unit Cell and Gene Montpellier (CHU)
  • Alboukadel Kassambara, PhD, Co-Founder, Postdoctoral position in Bioinformatic and research on Myeloma Biology into the laboratory « Monitoring Innovative Therapies » at the Montpellier University Hospital (CHU). Development of statistical tools for genomic data analysis
  • Philippe Pasero, PhD, Deputy Director of the Institute of Human Genetics (IGH Montpellier), Group leader of « Maintenance of Genome Integrity during DNA Replication » Department.
  • Guillaume Cartron, MD, PhD, Professeur of University (CHU Montpellier), Head of Hematology Department (UMR-CNRS 5235)
  • International experts recruitment – On going

They support Diag2Tec

  • Diag2Tec is supported by BPIFrance, the French SME funding organization and has been Nominated for « Creating innovative company » prize Ilab-2015.
  • Diag2Tec is supported and accompagned by the BIC (Business Innovation Center) of Montpellier Metropole and by The LRI (Languedoc Roussillon Incubator).
  • Diag2Tec is supported by TTO AxLR (chemogram maturation phase).
  • DIAG2TEC supported by CREALIA to improve the treatment of hematological cancers. Créalia allow them to strengthen their capital and accelerating the development of the company and especially R&D.
  • Diag2Tec is in demand (on going) to have a grant a Research Tax Relief (« Agrément Crédit Impôt Recherche ») by the French Ministry of Research and Technology.
  • Diag2Tec is in the process of applying for young innovative company « JEI, Jeune Entreprise Innovante » by the French Ministry of Research and Technology.